Healthcare Providers' Adherence to Breast Cancer Guidelines in Europe: a Systematic Literature Review

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2020 May 8

PMID 32378052

Citations 9

Authors

Ena Nino de Guzman

Yang Song

Pablo Alonso-Coello

Carlos Canelo-Aybar

Luciana Neamtiu

Elena Parmelli

Javier Perez-Bracchiglione

Montserrat Rabassa

David Rigau

Zuleika Saz Parkinson

Ivan Sola

Adrian Vasquez-Mejia

Ignacio Ricci-Cabello

Affiliations

Soon will be listed here.

Abstract

Purpose: Clinical guidelines' (CGs) adherence supports high-quality care. However, healthcare providers do not always comply with CGs recommendations. This systematic literature review aims to assess the extent of healthcare providers' adherence to breast cancer CGs in Europe and to identify the factors that impact on healthcare providers' adherence.

Methods: We searched for systematic reviews and quantitative or qualitative primary studies in MEDLINE and Embase up to May 2019. The eligibility assessment, data extraction, and risk of bias assessment were conducted by one author and cross-checked by a second author. We conducted a narrative synthesis attending to the modality of the healthcare process, methods to measure adherence, the scope of the CGs, and population characteristics.

Results: Out of 8137 references, we included 41 primary studies conducted in eight European countries. Most followed a retrospective cohort design (19/41; 46%) and were at low or moderate risk of bias. Adherence for overall breast cancer care process (from diagnosis to follow-up) ranged from 54 to 69%; for overall treatment process [including surgery, chemotherapy (CT), endocrine therapy (ET), and radiotherapy (RT)] the median adherence was 57.5% (interquartile range (IQR) 38.8-67.3%), while for systemic therapy (CT and ET) it was 76% (IQR 68-77%). The median adherence for the processes assessed individually was higher, ranging from 74% (IQR 10-80%), for the follow-up, to 90% (IQR 87-92.5%) for ET. Internal factors that potentially impact on healthcare providers' adherence were their perceptions, preferences, lack of knowledge, or intentional decisions.

Conclusions: A substantial proportion of breast cancer patients are not receiving CGs-recommended care. Healthcare providers' adherence to breast cancer CGs in Europe has room for improvement in almost all care processes. CGs development and implementation processes should address the main factors that influence healthcare providers' adherence, especially patient-related ones.

Registration: PROSPERO (CRD42018092884).

Citing Articles

Health Information Needs of Breast Cancer Survivors: An Umbrella Review.

Gavili N, Sedghi S, Panahi S, Razmgir M Breast J. 2025; 2024:5889622.

PMID: 39742372 PMC: 11262878. DOI: 10.1155/2024/5889622.

Prescriptive appropriateness in early breast cancer staging exams: preliminary investigation about adherence to the guidelines in the clinical practice.

Errico A, Di Rito A, Sallustio A, Bardoscia L, Bambace S, Portaluri M Acta Biomed. 2023; 94(5):e2023204.

PMID: 37850779 PMC: 10644928. DOI: 10.23750/abm.v94i5.14228.

Characteristics and impact of interventions to support healthcare providers' compliance with guideline recommendations for breast cancer: a systematic literature review.

Ricci-Cabello I, Carvallo-Castaneda D, Vasquez-Mejia A, Alonso-Coello P, Saz-Parkinson Z, Parmelli E Implement Sci. 2023; 18(1):17.

PMID: 37217955 PMC: 10201699. DOI: 10.1186/s13012-023-01267-2.

Staging for Breast Cancer: A Nationwide Survey about Adherence to Guidelines in German Breast Centers.

Jannes M, Konig A, Kolben M, Fridrich C, Kirn V Breast Care (Basel). 2022; 17(3):316-320.

PMID: 35957950 PMC: 9247493. DOI: 10.1159/000521967.

Real-World Breast Cancer Patient Follow-Up Practices by Medical Oncologists in India-A Survey Report.

Patel A, Gupta V, Guleria B, Das C, Mehta P, Ramegowda K South Asian J Cancer. 2022; 11(1):9-13.

PMID: 35833040 PMC: 9273312. DOI: 10.1055/s-0041-1739187.

References

Schwentner L, Wockel A, Konig J, Janni W, Ebner F, Blettner M . Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9,156 patients. BMC Cancer. 2013; 13:487. PMC: 3815231. DOI: 10.1186/1471-2407-13-487. View

Schaapveld M, de Vries E, van der Graaf W, Otter R, Willemse P . Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study. J Cancer Res Clin Oncol. 2004; 130(10):581-90. DOI: 10.1007/s00432-004-0583-6. View

Jensen A, Mikkelsen G, Vestergaard M, Lynge E, Vejborg I . Compliance with European guidelines for diagnostic mammography in a decentralized health-care setting. Acta Radiol. 2005; 46(2):140-7. DOI: 10.1080/02841850510015929. View

van Fenema E . [Assessment of guideline adherence and quality of care with routine outcome monitoring data]. Tijdschr Psychiatr. 2017; 59(3):159-165. View

de Bock G, Vliet Vlieland T, Hakkeling M, Kievit J, Springer M . GPs' management of women seeking help for familial breast cancer. Fam Pract. 1999; 16(5):463-7. DOI: 10.1093/fampra/16.5.463. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

Schreuder K, Kuijer A, Rutgers E, Smorenburg C, van Dalen T, Siesling S . Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area. Eur J Cancer. 2017; 84:270-277. DOI: 10.1016/j.ejca.2017.07.042. View

Gandhi S, Verma S, Ethier J, Simmons C, Burnett H, Alibhai S . A systematic review and quality appraisal of international guidelines for early breast cancer systemic therapy: Are recommendations sensitive to different global resources?. Breast. 2015; 24(4):309-17. DOI: 10.1016/j.breast.2014.12.005. View

Schaapveld M, de Vries E, Otter R, de Vries J, Dolsma W, Willemse P . Guideline adherence for early breast cancer before and after introduction of the sentinel node biopsy. Br J Cancer. 2005; 93(5):520-8. PMC: 2361605. DOI: 10.1038/sj.bjc.6602747. View

10.

Liebrich C, Unger G, Dlugosch B, Hofmann S, Petry K . Adopting Guidelines into Clinical Practice: Implementation of Trastuzumab in the Adjuvant Treatment of Breast Cancer in Lower Saxony, Germany, in 2007. Breast Care (Basel). 2011; 6(1):43-50. PMC: 3083270. DOI: 10.1159/000324048. View

11.

de Munck L, Schaapveld M, Siesling S, Wesseling J, Voogd A, Tjan-Heijnen V . Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands. Breast Cancer Res Treat. 2011; 129(1):229-33. DOI: 10.1007/s10549-011-1451-0. View

12.

Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, De Tursi M . Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey. PLoS One. 2014; 9(4):e94063. PMC: 3979748. DOI: 10.1371/journal.pone.0094063. View

13.

Visser A, van de Ven E, Ruczynski L, Blaisse R, van Halteren H, Aben K . Cardiac monitoring during adjuvant trastuzumab therapy: Guideline adherence in clinical practice. Acta Oncol. 2015; 55(4):423-9. DOI: 10.3109/0284186X.2015.1068444. View

14.

Ganann R, Ciliska D, Thomas H . Expediting systematic reviews: methods and implications of rapid reviews. Implement Sci. 2010; 5:56. PMC: 2914085. DOI: 10.1186/1748-5908-5-56. View

15.

Seroussi B, Laouenan C, Gligorov J, Uzan S, Mentre F, Bouaud J . Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support?. Br J Cancer. 2013; 109(5):1147-56. PMC: 3778303. DOI: 10.1038/bjc.2013.453. View

16.

Ebner F, van Ewijk R, Wockel A, Hancke K, Schwentner L, Fink V . Tumor biology in older breast cancer patients--what is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohort study of 5378 patients. Breast. 2015; 24(3):256-62. DOI: 10.1016/j.breast.2015.02.029. View

17.

Schwentner L, Wolters R, Wischnewsky M, Kreienberg R, Wockel A . Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients. Breast. 2011; 21(2):171-7. DOI: 10.1016/j.breast.2011.09.007. View

18.

van Ewijk R, Wockel A, Gundelach T, Hancke K, Janni W, Singer S . Is guideline-adherent adjuvant treatment an equal alternative for patients aged >65 who cannot participate in adjuvant clinical breast cancer trials? A retrospective multi-center cohort study of 4,142 patients. Arch Gynecol Obstet. 2014; 291(3):631-40. DOI: 10.1007/s00404-014-3438-7. View

19.

Wollschlager D, Meng X, Wockel A, Janni W, Kreienberg R, Blettner M . Comorbidity-dependent adherence to guidelines and survival in breast cancer-Is there a role for guideline adherence in comorbid breast cancer patients? A retrospective cohort study with 2137 patients. Breast J. 2017; 24(2):120-127. DOI: 10.1111/tbj.12855. View

20.

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M . Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018; 103:356-387. DOI: 10.1016/j.ejca.2018.07.005. View